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Abstract
Background
This two-year study is a retrospective analysis of records of patients diagnosed with gastro-oesophageal reflux disease (GORD) at a private 
medical aid society for the period January 2002 to December 2003. In this study of GORD and its complications, the use of gastroscopy as 
a staging criteria and the cost of treatment were evaluated. Patients with alarming symptoms (chronic gastrointestinal bleeding, progressive 
unintentional weight loss, progressive difficulty in swallowing, persistent vomiting, iron deficiency anaemia, epigastric mass or suspicious 
barium meal), those with complications of GORD (erosive oesophagitis, ulcerative oesophagitis, oesophageal strictures, Barrett’s oesopha-
gus and oesophageal adenocarcinoma), and patients in whom symptoms have not resolved need to have a gastroscopy performed. If left 
untreated, some of these symptoms could lead to more severe and serious complications. Accurate recognition of these symptoms will 
help to identify, evaluate and treat patients timeously. The use of the gastroscopy allows for the detection of complications of GORD, which 
helps to identify patients with complications timeously and avoids, delays or stops the progression of the complications of GORD. However, 
the unnecessary use of gastroscopy in patients without complications results in unnecessary costs. Patients without alarming symptoms or 
complications should be treated empirically with proton pump inhibitors (PPIs) to resolve the symptoms of GORD.
Methods
One thousand seven hundred and fifty-three patients with GORD were identified from computer records at a private medical aid society for 
the period January 2002 to December 2003. These patient records were retrospectively analysed using the computer database. All newly 
diagnosed GORD patients (n = 586) who were on drug therapy were included in the study. These patients were divided into two subsets: 
those without gastroscopy (n = 211) and those with gastroscopy (n = 375). The latter group was further identified as those that had under-
gone one (n = 232) or more than one gastroscopy (n = 143). Patients were further subdivided into those with and without complications. 
The choice of the study population was not based on the complication or the severity of the symptoms, but on whether or not the attending 
doctor chose to have a gastroscopy done. 
Results 
The number of complications detected in patients with more than one gastroscopy was the highest (34%; n = 48) in comparison to patients 
with one gastroscopy (21%; n = 49) or without gastroscopy (7%; n = 15) (p < 0.001). The odds or chances of having complications were 
significantly greater in patients with one gastroscopy compared to those without gastroscopy (OR 3.5; 95% CI: 1.8-6.9). Having an additional 
gastroscopy increased the odds of complications significantly compared to patients with just one gastroscopy (OR 1.9; 95% CI: 1.1-3.1). 
Barrett’s oesophagus occurred in 1.9% (n = 4) of patients without gastroscopy and in 15.7% (n = 59) of patients with gastroscopy (p < 
0.001). 
Discussion
Patients without gastroscopy presented with the lowest number of complications. The performance of gastroscopy in patients with alarming 
symptoms or complications may have resulted in more complications being detected. In subjects without gastroscopy, the prevalence of 
Barrett’s oesophagus was low. The proportion of subjects with complications is strongly associated with the number of gastroscopies they 
had undergone. Multiple gastroscopies increased the likelihood of detecting complications. Thus, a gastroscopy should only be performed 
if the symptoms of GORD do not resolve or if the patient has alarming symptoms or complications after empirical therapy.
Conclusion
The performance of gastroscopy in patients who had not undergone a gastroscopy before may have resulted in more complications being 
detected. Having more than one gastroscopy significantly increased the odds of detecting complications compared to patients with who 
had only undergone one gastroscopy. Patients without alarming symptoms should be treated empirically for one to two months, and a gas-
troscopy should only be performed if the symptoms do not resolve or if the patients experience complications or alarming symptoms.1 This 
study was confined to a single medical aid society. For comparison, other medical aids should be included.
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Introduction
Gastro-oesophageal reflux disease 
(GORD) occurs when hydrochloric 
acid from the stomach refluxes into the 
oesophagus, thus causing inflammation 
in or injury to the oesophagus.2 GORD 
is diagnosed by subjective symptoms 
(e.g. heartburn) and objective criteria 
(gastroscopy, ambulatory pH monitor-
ing).
When a patient experiences the symp-
toms of GORD, the first option would 
appear to be for a gastroscopy to be 
performed. However, patients without 
alarming symptoms should be treated 
empirically for two months for the symp-
toms to be resolved.1 Most patients 
experience relief from the symptoms of 
GORD after a few months of treatment 
with proton pump inhibitors (PPIs). 
However, patients with complications of 
GORD (erosive oesophagitis, ulcerative 
oesophagitis, oesophageal strictures, 
Barrett’s oesophagus and oesophageal 
adenocarcinoma) or alarming symptoms 
(chronic gastrointestinal, bleeding; pro-
gressive unintentional weight loss, pro-
gressive difficulty in swallowing, persis-
tent vomiting, iron deficiency anaemia, 
epigastric mass or suspicious barium 
meal), or those in whom symptoms have 
not resolved, require gastroscopy to be 
performed.1 A second gastroscopy may 
need to be undertaken to evaluate for 
underlying Barrett’s oesophagus that 
may have been missed on the initial 
examination. 
Method
This study is a retrospective analysis of 
patients diagnosed with GORD at a pri-
vate medical aid society. This large pri-
vate medical aid society has members 
nationally. The study reviewed patient 
records. A request was submitted to the 
Information Technology (IT) department 
for information to be extracted from the 
database for a period of two years. 
The study population comprised South 
Africans of African decent, Coloureds, 
Asians, and whites. The medical re-
cords of all patients diagnosed with 
GORD, with or without gastroscopy, 
were reviewed. Data requested from the 
IT department of the Sovereign Health 
National Medical Plan (NMP) included 
the following:
•  The number of all current, active new-
ly-diagnosed patients with GORD 
• The age/race/sex of the subjects
•  The number of gastroscopies (gr) 
performed on each subject within the 
time frame
•  The number of patients that did not 
have gastroscopy within the study 
period
• History of concurrent illnesses
•  History of medication for GORD and 
concurrent illnesses
• Complications of GORD
• The duration of GORD treatment
•  The cost of drug therapy with or with-
out gastroscopy
• The cost of gastroscopy
• Cost of complications of GORD
Ethical clearance was obtained from the 
University of KwaZulu-Natal. Permission 
to access medical aid information was 




• On current treatment for GORD
• No previous treatment for GORD
Exclusion criteria:
• Previous treatment for GORD
• Intermittent treatment for GORD
• Non-compliant subject
•  Subjects who died (cause of death 
was non-GORD related)
Results
Figure 1 provides a graphic representa-
tion of the data relating to the subjects 
that were included in the study and 
those that were excluded.
The two subsets (with gastroscopy 
and without gastroscopy) were equally 
matched for sex, age and ethnicity. The 
directly-related medical conditions as-
sociated with GORD were diaphragmat-
ic hernia, anaemia and peptic ulcer. The 
indirectly-related concurrent medical 
conditions identified were osteoporosis, 
osteoarthritis, asthma, rheumatoid ar-
thritis and angina pectoris. NSAIDS, cal-
cium channel blockers, aspirin, COXIB 
inhibitor, COX II inhibitor, enteric-coated 
aspirin and alendronate were the most 
commonly used drugs that affect GORD 
in both the subsets.
Complications were detected in a 
third of the patients (34%) with more 
than one gastroscopy. In patients with 
one gastroscopy, complications were 
detected in 21% of the patients and in 
patients without gastroscopy the com-
plications were only detected in 7%. 
Table 1 provides an analysis of pa-
tients with and without complications 
in patients that did or did not have a 
gastroscopy.































0 1 > 1 Total
Complications 7 (15) 21 (49) 34 (48) 25.9 (97)
Without complications 93 (196) 79 (183) 66 (95) 74.1 (278)
Total 211 232 143 375
Table I: Analysis of complications in patients with or without gastroscopy.
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Barrett’s oesophagus was found in 1.9% 
(n = 4) of patients without gastroscopy 
and in 15.7% (n = 59) of patients with 
gastroscopy (see Table II). Barrett’s oe-
sophagus was found to be statistical-
ly significant in patients with and with-
out gastroscopy (p < 0.001). The subset 
with gastroscopy included a higher per-
centage of white male patients with Bar-
rett’s oesophagus.
Table 11 shows an anlysis of patients 
detected with the different complica-
tions of GORD in patients with or without 
gastroscopy.
A total of 9.5% of patients without 
gastroscopy (n = 20) had been treated 
for GORD for less than six months and 
32% (n = 120) of patients with gastros-
copy had been treated for less than six 
months. Of the patients without gastros-
copy, 76.3% (n = 161) had been treat-
ed for more than 12 months and 38% 
(n = 142) of the patients with gastros-
copy had been treated for more than 
12 months.
The approximate cost of gastroscopy 
per subject was R338 for the two-year 
period (2002 to 2003). The approximate 
cost of drugs per subject with gastros-
copy was R7 672 for the two-year peri-
od. This gives a total cost of treatment 
per subject with gastroscopy of ap-
proximately R8 010 per two-year peri-
od. This cost includes the cost of drugs 
and gastroscopy and excludes theatre 
fees, gastroenterologist consultation, 
ward fees and theatre drugs. The cost 
of treatment per subject without gastros-
copy was approximately R2 127. 
The costs shown in the schemat-
ic representation in Figure 2 below in-
clude the cost of drugs and gastrosco-
py (R338) per subject (2002 to 2003). 
For example, in patients with Barrett’s 
oesophagus, the cost of the drugs was 
R6 272 and the cost of the gastrosco-
py was R338. In combination, the total 
cost for both gastroscopy and drugs 
was R6 610.
Figure 2 represents the cost of drugs 
and gastroscopy per subject
Proton pump inhibitors (PPI) were 
used in 84% (178) of patients without 
gastroscopy and in 87.6% (331) pa-
tients with gastroscopy. 
Discussion
Osteoporosis, osteoarthritis, asthma 
and rheumatoid arthritis occurred in 
similar frequency in both the population 
groups. The drugs used for these diag-
noses aggravate GORD. NSAIDS, cal-
cium channel blockers, aspirin, COX-
IB inhibitor, COX II inhibitor, enteric-
















Ulcerative oesophagitis 0.5 (1) 3 (7) 2.7 (4) 3 (11) 0.06
Oesophageal erosions 0.5 (1) 1 (3) 2.7 (4) 1.9 (7) 0.3
Oesophageal stricture 3 (6) 2.4 (6) 4.8 (7) 3.4 (13) 0.8
Barrett’s oesophagus 2 (4) 12 (28) 21.7 (31) 15.7 (59) <0.001
Cough 0 (0) 0.4 (1) 0(0) 0.3 (1) 0.9
Chest pain 0 (0) 2 (4) 0(0) 1.2 (4) 0.3
Dyspnoea (nocturnal) 0.5 (1) 0(0) 0(0) 0 0.4
Reflux laryngitis 0.5 (1) 0(0) 0.7 (1) 0.3 (1) 0.9
Reflux into mouth 0 (0) 0(0) 0.7 (1) 0.3 (1) 0.9
Table II: Complications directly related to GORD in patients with or without gastroscopy
Figure 2:  Schematic representation of cost of drugs and gastroscopy per subject (January 


























the most commonly used drugs that af-
fect GORD in both the subsets. Calci-
um channel blockers, biphosphonates 
and NSAIDs have been mentioned in 
the NICE guidelines as possible causes 
of dyspepsia.1 Drugs used for concur-
rent diagnoses that aggravate GORD 
need to be discontinued and an alterna-
tive treatment should be considered. If 
these drugs cannot be discontinued, a 
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proton pump inhibitor should be added 
to the subject’s drug treatment.
Patients without gastroscopy present-
ed with the lowest number of complica-
tions. The performance of gastroscopy 
in these patients may have resulted in 
more complications being detected. 
The decision to perform a gastroscopy 
should be based on whether the sub-
ject had complications of GORD or if 
the symptoms of GORD had not been 
resolved after empirical therapy.1 The 
clinician needs to base his/her diagno-
sis on objective evidence (gastroscopy) 
and not only on symptoms. Patients 
with serious complications may remain 
undetected.
A total of 74.1% of the study popula-
tion with gastroscopy presented without 
complications. Patients without alarming 
symptoms should be treated empirically 
for two months, which would eliminate 
the need for gastroscopy and hence 
reduce medical expenses.1 There 
would have been a cost saving in direct 
(gastroscopy) and indirect (theatre fees, 
gastroenterologist consultation, ward 
fees, theatre drugs) medical expenses. 
One of the key discussions and conclu-
sions in the GENVAL Guidelines was 
that patients with a typical history of 
uncomplicated GORD should be given 
empirical therapy after careful symptom 
analysis without diagnostic investiga-
tion.3 If this fails, or if the subjects have 
symptoms suggesting complications, 
they should undergo a gastroscopy. The 
South African Gastroenterologists Soci-
ety (SAGES) supports and endorses the 
GENVAL guidelines.4 Gastroscopy is 
indicated if the symptoms continue or 
if the patients develop complications. 
These guidelines are not being adhered 
to. 
According to the NICE guidelines, 
routine endoscopic investigation of 
patients presenting with dyspepsia 
and without alarming symptoms is not 
necessary.1 However, for patients over 
55 years of age with complications, 
gastroscopy should be considered. 
According to the NICE guidelines, a 
subject presenting with dyspepsia and 
without alarming symptoms should be 
offered one to two months of full-dose 
PPI. The American College of Gastro-
enterology(5) and the British Society of 
Gastroenterology (BSG) also suggests 
empirical treatment with PPIs in patients 
without alarm symptoms. 6  The South 
African Gastroenterologists Society 
(SAGES) supports the BSG in its posi-
tion statements and guidelines.(7)
The percentage of patients without com-
plications in both the groups confirms 
that the two groups in this study were 
not chosen on the basis of their compli-
cations. Patients with gastroscopy were 
further subdivided into those having had 
one and those having had more than 
one gastroscopy. There was a statisti-
cally significant difference in detecting 
complications between the patients with 
one or more than one gastroscopy (p 
<0.001). The proportion of patients with 
complications being detected is sig-
nificantly associated with the number of 
gastroscopies they had undergone. The 
odds or chances of detecting complica-
tions were significantly greater in pa-
tients with a single gastroscopy than in 
those without gastroscopy. Having had 
more than one gastroscopy increased 
the odds of detecting complications 
significantly compared to patients with 
just one gastroscopy (OR 1.9; 95% CI: 
1.1-3.1). 
This is in accordance with interna-
tional guidelines, which recommend 
more than one gastroscopy in non-
resolving complications of GORD. 
Gastroscopy is necessary in patients 
with complications and in whom symp-
toms have not resolved. Patients with 
oesophageal complications of GORD 
need to be diagnosed objectively with 
a gastroscopy. Certain patients with 
oesophageal complication may require 
more than one gastroscopy to monitor 
serious complications.
Gastroscopy is a diagnostic tool and 
the lack of its use in some patients may 
account for the small number of cases 
of Barrett’s oesophagus detected in 
patients without gastroscopy (n = 4). 
Patients with complications of GORD 
should undergo endoscopic evalua-
tion. Gastroscopy is essential to detect 
Barrett’s oesophagus, thus endoscopic 
surveillance every two to three years 
may be inappropriate, since Barrett’s 
oesophagus has to be treated quickly 
and as early as possible. If dysplasia 
is detected, gastroscopy needs to be 
performed on a yearly basis.8 When low-
grade dysplasia is present, the interval 
is shortened to every six months for one 
year, followed by annual surveillance. If 
high-grade dysplasia is detected on bi-
opsy, an expert histopathologist should 
confirm the findings. When the confirma-
tion is consistent with high-grade dys-
plasia, surveillance every three months 
is appropriate.9,10
The mean age of development of 
Barrett’s oesophagus is estimated to be 
40 years, yet the mean age at diagnosis 
is 63 years. This suggests that a prema-
lignant disorder may be present for up 
to 20 years before it is clinically recog-
nised.9 The timeous investigation of pa-
tients with complications may avoid or 
delay the progression of complications 
of GORD. The diagnosis of Barrett’s de-
pends upon a histological examination, 
with the finding of intestinal goblet cells 
in the oesophageal biopsies. Although 
the diagnosis is made histologically, 
one should have a high index of suspi-
cion for Barrett’s oesophagus in patients 
with a long history of reflux symptoms.11 
Some patients who have suffered with 
heartburn find that the heartburn has 
become less severe or has disap-
peared over recent months or years. 
This is because patients with Barrett’s 
oesophagus often lose their sensitivity 
to acid and bile reflux, probably on the 
basis of damage to sensory nerves in 
the oesophageal mucosa.11
More patients (76.3%) without gas-
troscopy were treated for longer than 
12 months in comparison to patients 
with gastroscopy. This was statistically 
significant (p <0.001). Although patients 
had a lower percentage of complica-
tions in these groups, they were treated 
for a longer period of time. If these pa-
tients had a gastroscopy done, more 
complications may have been detected. 
Patients with complications need to be 
treated for a longer period of time. This 
is due to the mucosal damage that has 
occurred over a period of time, leading 
to serious complications (Barrett’s oe-
sophagus, oesophageal strictures). Ac-
cording to the NICE guidelines, patients 
who have severe GORD symptoms or 
who have a proven pathology (e.g. oe-
sophageal ulceration, Barrett’s oesoph-
agus) should be treated with a higher 
healing dose of a PPI until symptoms 
have been controlled.1 Patients without 
gastroscopy need to be objectively as-
sessed in order to determine whether 
they have complications to warrant a 
longer duration of treatment with PPIs.
Based on the results obtained, one 
could recommend that patients with 
uncomplicated GORD be treated for 
two months with empirical PPI therapy. 
Gastroscopy should only be performed 
if the symptoms do not resolve or if these 
patients experience complications or 
alarming symptoms. However, the only 
exception to this would be patients older 
than 55 years who present with symp-
toms of GORD for the first time, on whom 
a gastroscopy should be performed.1
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The costs for patients with gastroscopy 
examined in this study included the 
cost of drugs and gastroscopy and ex-
cluded theatre fees, gastroenterologist 
consultations, ward fees and theatre 
drugs. The cost of treatment per sub-
ject for patients with gastroscopy was 
3.8 times more than that for patients 
without gastroscopy. However, gas-
troscopy is an objective criteria that 
leads to the detection of complications 
and hence more intense and directed 
treatment. 
It would seem that it is less expen-
sive to treat those patients who have 
not undergone gastroscopy. However, 
based on pharmaco-economic prin-
ciples, it costs more in the long term to 
treat patients who had not undergone 
a gastroscopy. Undetected and there-
fore untreated complications result 
in resistance to treatment and a pro-
longed healing time, which may lead to 
Barrett’s oesophagus and adenocarci-
noma. This causes costs to escalate. 
While the cost per patients for the 
subset with gastroscopy was higher, 
the diagnosis of GORD was conclu-
sive. Therefore, it allows for targeted 
therapy based on conclusive evidence. 
Although the expenses incurred in the 
subset with gastroscopy are higher, it 
is more cost effective in the long term 
since the complications will be treated 
promptly. 
Proton pump inhibitors were the 
most commonly used drugs in patients 
with and without gastroscopy. This 
concurs with international and national 
guidelines, which advocate the use of 
PPIs as first-line agents in GORD. PPIs 
form the cornerstone of treatment for 
GORD and have been documented 
to be superior to H2-receptor antago-
nists (H2RA) in meta-analyses for the 
healing of erosive oesophagitis.(12)A
ccording to this study, the PPI most 
commonly used in patients with and 
without gastroscopy was lansoprazole, 
while omeprazole was the second 
most commonly prescribed PPI. This 
may be due to omeprazole and lan-
soprazole being on the market for the 
longest or due to the cheaper generic 
products available. 
Conclusion
In this retrospective analysis of patients 
diagnosed with GORD at a private 
medical aid, the following were found:
•  Patients in the subset with gas-
troscopy had more complications 
of GORD than those in the subset 
without gastroscopy.
•  Patients with complications of GORD 
or in whom symptoms had not 
resolved require objective criteria 
(gastroscopy) to diagnose GORD. 
These complications include oe-
sophageal erosions, oesophageal 
ulcer, oesophageal stricture and 
Barrett’s oesophagus.
•  The patients with gastroscopy who 
did not have complications should 
first have been treated empirically 
instead of having a gastroscopy 
performed. Gastroscopy should not 
be used unnecessarily unless there 
are complications or if symptoms do 
not resolve.
•  Patients without gastroscopy were 
treated for a longer time than com-
pared with patients with gastrosco-
py. The guidelines were not followed 
in these patients. Patients without 
complications should be treated 
empirically for one to two months. 
The cost of treatment seemed low-
er for patients without gastroscopy. 
However, based on pharmaco-eco-
nomic principles, it costs more in 
the long term to treat patients who 
have not undergone a gastrosco-
py. This could be due to undetect-
ed, untreated and therefore resis-
tant complications. 
•  Drugs like NSAIDS, alendronate, 
calcium channel blockers and the-
ophylline aggravate GORD. These 
drugs should be discontinued and, 
if they cannot be discontinued, the 
use of PPIs for the protection of the 
gastric mucosa is recommended.
The NICE guidelines recommend that 
the routine endoscopic investigation 
of patients of any age presenting with 
dyspepsia and without alarm signs 
is not necessary. These patients 
should be treated empirically for ap-
proximately one to two months before 
undergoing a gastroscopy. A gas-
troscopy should only be performed if 
the symptoms persist or if there are 
complications of GORD. Gastroscopy 
is an objective criterion that detects 
complications in patients with GORD. 
It is not indicated if there are no com-
plications. However, in patients aged 
55 years and older with unexplained 
and persistent recent-onset dyspepsia 
alone, an urgent referral for endoscopy 
should be made.
Limitations
This study was confined to a single 
medical aid society. For comparison, 
other medical aids should be included. 
For the results to be more generalis-
able, it would be necessary to con-
duct research on mixed populations 
which include subjects of high and 
low income. The study population was 
restricted to people who could afford 
medical aid, which may be a source of 
selection bias.
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